Several pharmacologic agents are now in clinical trials that aim to compete with therapeutic plasma exchange (TPE) for common autoimmune indications. We will discuss medications such FcRn antagonists and IdeS enzymes that reduce IgG levels in the serum similar to TPE. Other drugs utilize different mechanisms of actions than TPE such as eculizumab, which inhibits C5 limiting antibody effector function, and caplacizumab, which prevents the interaction between von Willebrand factor and platelets.
In this session, we will cover the mechanism and emerging preclinical and clinical data for these newer emerging pharmacologic agents. We will focus on the strengths and weaknesses of these approaches compared to TPE and speculate on the potential utility of combining these agents with TPE for the best care of patients in the future.
Explain the mechanism of FcRn inhibitors in reducing IgG levels and describe emerging data
Indicate how IdeS enzymes work against IgG, and describe available clinical data
Describe the mechanism of eculizumab and caplacizumab, and describe available evidence and indications
Division Director of Transfusion Medicine Services,
Houston Methodist Hospital